Chronic hepatitis B, biological basis for new therapeutic strategies.
Dianzani
F
F
Institute of Virology, University La Sapienza, Roma, Italy.
D015075:2-Aminopurine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000821:virology; D000077595:Famciclovir; D006515:Hepatitis B virus / Q000235:genetics* / Q000472:pathogenicity*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000150:complications / Q000821:virology; D009154:Mutation; D011355:Prodrugs / Q000494:pharmacology / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D014779:Virus Replication
D000998:Antiviral Agents; D011355:Prodrugs; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015075:2-Aminopurine; D000077595:Famciclovir